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Mpn1 is an exoribonuclease that modiﬁes the spliceosomal small nuclear RNA (snRNA) U6 by trim-
ming its oligouridine tail and introducing a cyclic phosphate group (>p). Mpn1 deﬁciency induces U6
30 end misprocessing, accelerated U6 decay and pre-mRNA splicing defects. Mutations in the human
MPN1 gene are associated with the genodermatosis Clericuzio-type poikiloderma with neutropenia
(PN). Here we present the deep sequencing of the >p-containing transcriptomes of mpn1D ﬁssion
yeast and PN cells. While in yeast U6 seems to be the only substrate of Mpn1, human Mpn1 also pro-
cesses U6atac snRNA. PN cells bear unstable U6atac species with aberrantly long and oligoadeny-
lated 30 ends. Our data corroborate the link between Mpn1 and snRNA stability suggesting that
PN could derive from pre-mRNA splicing aberrations.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Clericuzio-type poikiloderma with neutropenia (PN) is a rare
recessive inherited genodermatosis characterized by early onset
poikiloderma, non-cyclic neutropenia, pachyonychia, palmoplantar
hyperkeratosis and skeletal defects [1–4]. PN patients carry
homozygous or compound heterozygous mutations in the human
gene C16ORF57, which encodes the evolutionarily conserved RNA
exonuclease human Mpn1 (hMpn1, also dubbed Usb1) [5–8].
Mpn1 proteins were originally assigned to the 2H phosphodi-
esterase superfamily and indeed they contain two typical tetrapep-
tide motifs H-X-T/S-X, where X is a hydrophobic residue [4,9]. Yet,
crystal structure and in vitro biochemical data have shown that
Mpn1 proteins are 30-to-50 single stranded RNA exonucleases with
a metal-independent catalytic activity generating a 20,30 cyclic
phosphate (>p) group at the 30 end of the reaction product [5,7].
hMpn1 enzymatic activity is completely abolished in mutant
recombinant proteins carrying histidine-to-alanine substitutions
within both tetrapeptide motifs and the majority of the mutations
so far identiﬁed in PN patients lead to expression of truncated pro-
teins lacking at least the most C-terminal tetrapeptide motif [4–8].The only cellular target of Mpn1 identiﬁed so far is the spliceo-
some core component U6 snRNA. U6 is produced by RNA poly-
merase III (RNPIII)-mediated transcription and primary U6
transcripts comprise an oligouridine (oligo(U)) tail at their 30 ends
containing 4 template Us [10,11]. Upon transcription, U6 is
thought to be extended by oligouridylation executed by the
enzyme TUTase [12,13] and successively Mpn1 trims the elongated
oligo(U) tail to 5 Us blocked by a >p group [5–7,14]. The terminal
>p is stable in humans and in Schizosaccharomyces pombe while it
seems to be immediately cleaved to generate a 20 or 30 p group
in Saccharomyces cerevisiae [5–7]. Indeed, in normal cells, the
majority of cellular U6 terminates with 5 Us blocked by either
p or >p groups [10]. On the contrary, in all Mpn1-deﬁcient model
systems tested so far, including cells established from PN patients,
U6 carries longer oligo(U) tails lacking phosphate groups and ter-
minating with cis 20,30-diol end (AOH) groups instead. Moreover,
in Mpn1 deﬁcient cells, U6 molecules are unstable, indicating that
Mpn1 counteracts U6 degradation through cellular pathways
whose molecular details still need to be elucidated [5–7]. It has
also been shown that a minor fraction of cellular U6 carries
oligo(U) tails mono- or oligoadenylated at their 30 ends in normal
human cells, while in PN cells the fraction of adenylated U6 is dra-
matically increased [5]. Adenylation was suggested to be per-
formed by the non-canonical poly(A) polymerase Trf4 [5].
Despite having similar effects on U6 post-transcriptional modi-
ﬁcations, Mpn1 inactivation has different consequences in differ-
ent organisms. In budding yeast, MPN1 deletion leads to cell
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viable, although they grow slower than wt cells in the cold. Both
yeast loss of function models show global defects in pre-mRNA
splicing and these defects, as well as the proliferation defects,
can be reverted by ectopic over-expression of U6, conﬁrming that
U6 becomes limiting upon Mpn1 deﬁciency [6,7]. Intriguingly,
human lymphoblastoid cells from PN patients do not display any
obvious defects in canonical pre-mRNA splicing, suggesting that
the impact of U6 misprocessing varies among different organisms
or, possibly, cell types [5,7]. Indeed, morpholino-mediated Mpn1
depletion in zebraﬁsh larvae induced aberrant splicing of a subset
of pre-mRNAs encoding polypeptides required for neutrophil dif-
ferentiation and development [15]. Injection of spliced mRNA in
Mpn1 depleted animals rescued neutrophil developmental defects,
indicating that splicing defects of a small subset of transcripts is
responsible for tissue-speciﬁc abnormalities [15]. Besides U6, no
other cellular substrate of Mpn1 has been identiﬁed so far, raising
the question of whether all defects associated to Mpn1 deﬁciency
arise from inappropriate U6 processing.
Here we present a next generation sequencing-based analysis of
the >p-containing transcriptome of ﬁssion yeast and human cells
lacking Mpn1 activity. While U6 appears to be the major if not
the only substrate for Mpn1 in yeast, human Mpn1 also processes
the snRNA U6atac, which is the U6-like snRNA found within the
minor spliceosome [17]. Similar to U6, U6atac carries aberrantly
elongated and often mono or oligoadenylated oligo(U) tails lacking
terminal phosphate groups and its stability is diminished in PN
cells. Our data further consolidate the proposed link between PN
and improper pre-mRNA splicing.2. Results
2.1. Deep sequencing of the >p-containing transcriptome identiﬁes
novel putative hMpn1 substrates
To isolate RNA substrates of Mpn1, we generated cDNA libraries
from 30 end >p-containing RNA species by ligating total RNA to an
oligonucleotide adaptor using Thaliana tRNA ligase, which speciﬁ-
cally ligates terminal >p to AOH groups [18]. For ﬁssion yeast sam-
ples, we used RNA prepared from wt and mpn1D strains [7]. For
human samples, we used RNA prepared from telomerase immor-
talized foreskin ﬁbroblasts established from a PN patient (PNFF
cells) stably infected with retroviruses expressing hMpn1
(PNFF-hMPN1) or, as a control, with empty vector retroviruses
(PNFF-ev) Ectopic hMpn1 is C-terminally tagged with an HA epi-
tope and expression was validated by western blot analysis (see
below). For sequence analysis, we applied an arbitrary cutoff and
considered only features with a normalized mapped read count
of at least 800 reads in Mpn1 proﬁcient samples, and at least a
10-fold enrichment in mapped reads in Mpn1 proﬁcient over deﬁ-
cient samples. Only U6 was identiﬁed as Mpn1 substrate in ﬁssion
yeast samples, with reads being 44-fold more abundant in wt than
in mpn1D samples (Fig. 1A). U6 reads clustered towards the 30 ter-
minus and 79% of them terminated with a stretch of 5 Us, conﬁrm-
ing that the large majority of >p-containing U6 oligo(U) tails
comprise 5 uridines (Fig. 1A and C).
As for the human samples, 12 transcripts passed our selection
criteria (Supplemental Table S1). Eight transcripts corresponded
to internal tracts of different mRNAs; the remaining 4 transcripts
corresponded to U6, U5 and U6atac snRNAs and Vault RNA 1-1
(VTRNA1-1). U6atac is the U6-like snRNA found within the minor
spliceosome, which catalyzes the removal of an atypical class of
introns (U12-type introns) found in vertebrates, plants, insects,
and some fungi [16,17]. VTRNA1-1 is a short non-coding RNA
found in the evolutionary conserved Vault particles, which areinvolved in diverse cellular processes such as multidrug and radi-
ation resistance, nuclear transport and immunity [19]. While reads
clustered towards the 30 end for U6, U6atac and VTRNA1-1, U5
reads were spread within the body of the transcript (Fig. 1B). The
presence of >p groups on internal mRNA and U5 sequences suggest
that >p groups could be generated on degraded or processed RNA
species rather than at the very 30 end of intact transcripts. We
therefore focused on U6, U6atac and VTRNA1-1. Similarly to what
was found for yeast U6, human U6 and U6atac 30 ends mostly com-
prised 5 Us, while a less strict consensus was observed for
VTRNA1-1, which often terminated with 2–4 Us (Fig. 1C).
2.2. U6atac is misprocessed in PN cells
To validate our next generation sequencing results, we per-
formed new ligations of total RNA from PNFF cells using Thaliana
tRNA ligase and, in parallel, using T4 RNA ligase, which only ligates
terminal AOH groups. In PNFF-hMPN1 samples, a large fraction of
U6 and approximately 50% of U6atac were ligated with Thaliana,
while U6 and U6atac were ligated with T4 but not Thaliana ligase
in PNFF-ev cells (Fig. 2A). VTRNA1-1 was efﬁciently ligated with
T4 but not Thaliana ligase in both PNFF-hMPN1 and PNFF-ev sam-
ples, yet we observed a very faint band corresponding to
Thaliana-ligated VTRNA1-1 speciﬁcally in PNFF-hMpn1 samples
(Fig. 2A, high contrast). As expected, 5S rRNA, which terminates
with AOH groups, was ligated by T4 RNA ligase and not by
Thaliana (Fig. 2A). Thus, in Mpn1-proﬁcient cells, the large majority
of U6, approximately half of U6atac and a very minor fraction of
VTRNA1-1 contain terminal 30 >p groups. To our knowledge, this
is the ﬁrst report on the existence of terminal >p groups on
U6atac and VTRNA1-1.
We then analyzed the electrophoretic mobility of U6, U6atac
and VTRNA1-1 using total RNA prepared from PNFF-ev and
PNFF-hMPN1 cells as well as from PNFF cells infected with three
hMpn1 variants carrying alanine to histidine substitutions within
their tetrapeptide motifs (hMPN1MA carries the mutation H120A;
hMPN1MB carries the mutation H208A; hMPN1DM carries both
mutations). All ectopic hMpn1 variants were expressed at similar
levels (Fig. 2B). In addition, we used RNA from two previously char-
acterized lymphoblastoid cell lines established from a PN patient
(P1) and his healthy brother (R1) [7,8]. As expected, U6 migration
was retarded in PNFF-ev and P1 samples as compared to
hMpn1-prociﬁent counterparts (Fig. 2C). Similarly, U6atac ran
more slowly in PNFF-ev and P1 samples, while VTRNA1-1 migra-
tion was not visibly affected (Fig. 2C). U6 and U6atac motilities
were retarded also in PNFF-hMPN1MB and PNFF-hMPN1DM cells
(Fig. 2B), conﬁrming that H208 is essential for hMpn1 enzymatic
activity. Unexpectedly, in PNFF-hMPN1MA samples U6 and U6atac
ran as in hMpn1 proﬁcient samples (Fig. 2A), which is in strike con-
trast with published data showing that hMpn1MA is catalytically
inactive in vitro and the corresponding mutant in budding yeast
cannot compensate for deletion of theMPN1 gene [5,6]. We suggest
that hMpn1MA retains substantial residual activity when expressed
in human cells. In this regard, it is interesting that no
PN-associated mutation has been reported to affect only the ﬁrst
tetrapeptide motif [4].
2.3. hMpn1 processes U6atac- and VTRNA1-1-like substrates in vitro
We previously established in vitro exonuclease assays utilizing
recombinant hMpn1 and hMpn1DM puriﬁed from bacteria and RNA
oligonucleotides mimicking the 30 end of human U6 [7]. We per-
formed similar assays using oligonucleotide substrates comprising
the last 13 residues of U6, U6atac and VTRNA1-1 sequences termi-
nating with 7 Us. We incubated oligonucleotides with recombinant
hMpn1 proteins for increasing time periods and analyzed reaction
Fig. 1. Analysis of >p-containing transcriptomes of Mpn1-deﬁcient yeast and human cells. (A) Read coverage plots of U6 in Mpn1-proﬁcient (mpn1+) and -deﬁcient (mpn1D)
S. pombe samples. The x axis indicates the coordinate along the transcript, and the y axis corresponds to the number of reads covering each base, after equalizing library sizes
between the two samples. (B) Read coverage plots of the indicated RNAs in Mpn1-deﬁcient (PNFF-ev) and compensated (PNFF-hMPN1) human ﬁbroblasts. (C) Most abundant
sequence tags (reads) assigned to the indicated RNA 30 ends in Mpn1-proﬁcient S. pombe and human samples. Their corresponding relative abundance is shown as % of all
reads assigned to the feature. Numbers on top left of each sequence indicate nucleotide positions. Oligo(U) tracts are shown in red.
Fig. 2. Mpn1-mediated processing of U6, U6atac and VTRNA1-1 30 ends. (A) Northern blot analysis of total RNA from PNFF-ev and PNFF-hMPN1 cells. Before electrophoresis,
RNA was ligated to an adaptor oligonucleotide with Thaliana tRNA ligase (Th) or with T4 RNA ligase (T4), or left untreated (–). The same membrane was hybridized
successively with probes detecting U6, U6atac, VTRNA1-1 and, as a control for ligation, 5S RNAs. LIG: ligated RNA species. (B) Western blot analysis of total protein extracts
from PNFF cells infected with retroviruses expressing full-length wt hMpn1, hMpn1 variants carrying the indicated mutations or with empty vector control retroviruses (eV).
The same membrane was consecutively probed with anti HA antibodies, to detect ectopic hMpn1 variants, and with anti UPF1 antibodies, to control for loading. (C) Northern
blot analysis of U6, U6atac and VTRNA1-1 using total RNA from the indicated PNFF-derived cell lines and from P1 (PN patient) and R1 (P1’s healthy brother) lymphoblastoid
cells. U5 and U1 were also detected to control for loading. (D) In vitro Mpn1 nuclease assays using recombinant wt hMpn1, double mutant (DM) hMpn1 or mock puriﬁcations
(eV). RNA oligonucleotide substrates correspond to the last 13 bases of U6, U6atac and VTRNA1-1 and terminate with 7 Us. Reaction products were collected at the indicate
time points and resolved in polyacrylamide gels. unt: Untreated RNA substrate.
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substrates were processed into a ladder of shorter species differing
from each other by one nucleotide (Fig. 2D). Oligonucleotide sub-
strates were not processed by hMpn1DM or mock puriﬁcation
extracts obtained from bacteria transformed with empty vector
expressing plasmids (Fig. 2D). The major hMpn1 reaction products,
which accumulated already at 0.2 min after addition of the
enzyme, corresponded to oligonucleotides terminating with 5 Us.
Products with less than 5 Us appeared with slower kinetics, when
reactions were further prolonged (Fig. 2D). It has been proposed
that hMpn1 utilizes the adenine 120 in U6 primary transcript as
a landmark to pause exonucleolytic activity thus preferentially
generating oligo(U) tails comprising 5 Us [5]. Nevertheless, the fact
that no adenine is present within 3 residues upstream of the
oligo(U) tracts in U6atac and VTRNA1-1 argues against this
hypothesis and rather suggests that hMpn1 might intrinsically be
able to count the number of Us comprised within the oligo(U) tract
of the substrate. Solving the crystal structure of Mpn1 in complex
with an RNA substrate should help clarifying this point.
2.4. Adenylated U6 and U6atac oligo(U) tails accumulate in Mpn1-
deﬁcient cells
Human U6 molecules from PN patients not only terminate with
an increased number of Us but they are also often adenylated or
oligoadenylated [5]. To test the conservation of this phenomenon
across species, we performed 30 end rapid ampliﬁcation of cDNA
ends (RACE) experiments followed by next generation sequencing
using total RNA fromwt andmpn1D yeast cells. To amplify all U6 30
ends regardless of the presence of phosphate groups, we ﬁrst trea-
ted total RNA with T4 polynucleotide kinase (PNK) in mild acidic
conditions to remove any kind of terminal phosphate group and
then ligated RNA to an adaptor oligonucleotide using T4 RNA
ligase. PCRs were performed using oligonucleotides speciﬁc for
the adaptor and the 50 end U6 sequences and ampliﬁcation prod-
ucts were deep sequenced. For sequence analysis, we only consid-
ered reads corresponding to full length U6 species, as we wanted to
exclude degradation products. In wt yeast cells, the large majority
of U6 terminated with 5 Us and a minor fraction of species with 4,
5 or 6 Us bore an additional A residue (Fig. 3A). Deletion of mpn1+
induced extensive U6 oligoadenylation with the majority of U6
species ending with 5 or 6 Us followed by one, or more rarely 2
or 3 As (Fig. 3A). To speciﬁcally sequence only U6 species terminat-
ing with AOH groups, we performed 30 end RACE using wt RNA not
treated with PNK and found an increased incidence of adenylated
U6 30 ends and oligo(U) tracts comprising 6 Us (Supplemental
Fig. S1A). This observation, together with the fact that no terminal
A was detected at U6 30 ends in our >p-containing transcriptome
sequencing of wt yeasts (Fig. 1C), indicates that adenylated U6
molecules do not contain >p groups. Therefore, the cyclic phospho-
rylation imposed by Mpn1 and adenylation appear to be mutually
exclusive. Terminal adenylation of U6 was suggested to depend on
the non-canonical poly(A) polymerase Trf4 [5]. Sequencing of U6 30
ends from yeast cells deleted for the gene encoding Cid14, the ﬁs-
sion yeast ortholog of Trf4, both inmpn1+ andmpn1D backgrounds
reveal no change in adenylation levels as compared to cid14+ cells
(Fig. 3A). We therefore conclude that Cid14/Trf4 does not play a
major role in U6 30 end adenylation, although we do not exclude
that alternative polymerases could compensate for Cid14/Trf4 loss.
We also performed 30 RACE of U6, U6atac and VTRNA1-1 using
PNK treated, total RNA from PNFF-ev and PNFF-hMPN1 human
cells. In hMpn1-compensated samples, U6 mostly terminated with
5 Us and was rarely adenylated, while it terminated with a more
variable number of Us comprised between 3 and 9 and was largely
adenylated or oligoadenylated in PNFF-ev cells (Fig. 3B). U6atac 30ends showed a less strict consensus than U6 as they terminated
with 3–7 Us and the levels of adenylation were higher than for
U6 in PNFF-hMPN1 samples. Yet, in PNFF-ev cells, U6atac mostly
terminated with 6–8 Us and was more abundantly adenylated
and oligoadenylated than in compensated cells (Fig. 3B). The anal-
ysis performed for VTRNA1-1 did not disclose any major differ-
ences between hMpn1 proﬁcient and deﬁcient samples
(Supplemental Fig. S1B). As for yeast, no terminal A was detected
at U6, U6atac and VTRNA1-1 30 ends in our >p-containing tran-
scriptome sequencing of PNFF-hMPN1 cells (Fig. 1C) indicating
that also in humans terminal A residues do not contain >p groups.
2.5. Mpn1 deﬁciency destabilizes U6atac
U6 stability is diminished in yeast and human cells lacking
Mpn1 activity [6,7] raising the possibility that hMpn1 also stabi-
lizes U6atac and VTRNA1-1. We measured the half-life of U6,
U6atac and VTRNA1-1 in PNFF ﬁbroblasts by incubating cells with
the global transcription inhibitor Actinomycin D (ACTD) and col-
lecting RNA samples over a time course of 3 h followed by northern
blot analysis. Similarly to what we previously found for PN lym-
phoblasts [7] U6 decayed faster in PNFF-ev cells than in compen-
sated cells, with half-lives of 73 and 174 min respectively
(Fig. 4A and B). Likewise, U6atac stability was lower in cells deﬁ-
cient for hMpn1 (half-lives of 45 min in PNFF-ev and 80 min in
PNFF-hMPN1; Fig. 4A and B). Thus, as is the case for U6, hMpn1
promotes stabilization of cellular U6atac. On the contrary, the
decay rates and half-life of VTRNA1-1 were similar in both cell
lines (Fig. 4A and B).
3. Discussion
While in ﬁssion yeast U6 is the major if not the only substrate
for Mpn1, in humans U6atac and possibly VTRNA1-1 are also pro-
cessed by hMpn1. The inﬂuence of hMpn1 on VTRNA1-1 30 end
modiﬁcations and stability are negligible at least in the cell types
that we have analyzed. On the contrary, the consequences of
hMpn1 deﬁciency on U6atac processing and stability are signiﬁ-
cant and parallel the ones on U6. We propose that, in cells lacking
functional hMpn1, the absence of a terminal >p group on U6 and
U6atac renders the 30 end of these RNA species accessible to exonu-
cleolytic degradation. In addition, a terminal >p group could also
directly prevent access and modiﬁcation of U6 and U6atac 30 ends.
For example, poly(A) polymerases would not be able to adenylated
oligo(U) tails as long as they are sealed by >p groups. This is indeed
in agreement with the observation that terminally adenylated 30
ends were never found in our >p-containing transcriptome analy-
sis. Trf4-mediated polyadenylation of RNA 30 ends is a common
signature found in RNA species targeted for degradation mediated
by the nuclear exosome [20]. By analogy, we propose that U6 and
U6atac molecules that are not processed by Mpn1 can be modiﬁed
by mono- or oligoadenylation, which would then ﬂag the RNA for
degradation. It is also possible that U6 and U6atac oligo(U) tails
are constitutively adenylated after transcription and hMpn1 suc-
cessively removes As thereby stabilizing the RNA. To directly test
these different hypotheses it will be essential to identify the poly-
merase that adenylates U6 and U6atac species accumulating in
Mpn1 deﬁcient cells.
Regardless of the precise molecular mechanisms promoting
RNA degradation in Mpn1 deﬁcient cells, it is clear that PN cells
suffer from de-regulated U6 and U6atac homeostasis. Yet, no global
pre-mRNA splicing defect is detectable in lymphoblasts and ﬁbrob-
lasts from PN patients [6,7] and similarly, RT-PCR-based analysis of
splicing of a selected number of U12 introns did not reveal any
major defect in PN cells (data not shown). It is therefore likely that
Fig. 3. RACE analysis of U6 and U6atac 30 ends. (A) Total RNA from the indicated ﬁssion yeast strains was treated with PNK and used for 30 RACE followed by deep sequencing.
Graphs show the fraction of reads corresponding to full-length intronless U6 terminating with the indicated number of uridines (x axis) and subsequent adenines (color coded
bars). Fractions are calculated with a denominator of 863,537 reads (wt), 1,134,499 reads (mpn1D), 461,210 reads (cid14D) or 433,811 reads (mpn1Dcid14D), representing all
reads terminating with 0 or more Us followed by 0 or more As. (B) Total RNA from PNFF-ev and PNFF-hMPN1 cells was treated with PNK and used for 30 RACE followed by
deep sequencing. Graphs show the fraction of reads corresponding to full-length U6 and U6atac terminating with the indicated number of uridines (x axis) and subsequent
adenines (color coded bars). Fractions are calculated with a denominator of 1,738,578 reads (PNFF-ev U6), 2,111,029 reads (PNFF-hMPN1 U6), 3,348,055 reads (PNFF-ev
U6atac) or 2,554,261 reads (PNFF-hMPN1 U6atac), representing all reads terminating with 0 or more Us followed by 0 or more As.
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certain tissues or during speciﬁc developmental stages. It is also
possible that only a restricted fraction of U2 and/or U12 introns
might be mispliced in cells lacking Mpn1, a possibility supported
by the observation of splicing defects of only some pre-mRNAs
involved in neutrophil differentiation and development, in
Mpn1-depleted zebraﬁsh embryos [15]. Moreover, a large number
of human U12 introns are spliced speciﬁcally upon stress through
stabilization of cellular U6atac, a process that might involve Mpn1
[21]. In order to understand the molecular bases of PN it seems
therefore necessary to develop mammalian models recapitulating
PN or to directly analyze pre-mRNA splicing in biopsies from
affected tissues from PN patients. We also consider the
non-mutual exclusive possibility that PN might derive from
de-regulation of non-spliceosomal pathways dependent on alter-
native hMpn1 substrates such as VTRNA1-1.4. Materials and methods
4.1. Plasmids
pBABE-HYGRO-MPN1 (hMPN1) and pBABE-HYGRO-MPN1-
H120A;H208A (hMPN1DM) were reported previously [7].
pBABE-HYGRO-MPN1-H120A (hMPN1MA) and pBABE-HYGRO-
MPN1-H208A (hMPN1MB) were generated by cloning gene synthe-
sized cDNAs (Genescript) into pBABE-HYGRO plasmids. All hMpn1
variants are C-terminally tagged with one HA epitope.4.2. Yeast strains and human cell lines
Wild type (CAF13; h-strain 972) and mpn1D (CAF41;
h Dmpn1::kanMX4) ﬁssion yeast strains were previously
described [7] cid14D (CAF382; h Dcid14::natMX6) and
mpn1Dcid14D (CAF383; h Dcid14::natMX6,Dmpn1::kanMX4)
strains were generated by replacing the entire cid14+ open reading
frame with a kanMX4 resistance cassette in CAF13 and CAF41,
respectively. All strains were maintained according to standard
laboratory procedures. Lymphoblastoid cell lines ML07136M (P1
in the text) derived from a PN patient and GGB04410M (R1)
derived from P1’s healthy brother were obtained from Galliera
Genetic Bank (Genova, Italy) and were previously described [7,8].
They were maintained in RPMI medium (Invitrogen) with 20% fetal
bovine serum, non-essential amino acids and penicillin/strepto-
mycin (Invitrogen). Foreskin ﬁbroblasts isolated from a PN patient
(PNFF) were immortalized by infection with hTERT-expressing
retroviruses according to standard protocols and maintained in
DMEM supplemented with 20% fetal bovine serum, non-essential
amino acids and penicillin/streptomycin (Invitrogen). For express-
ing wt and mutated hMpn1 variants, telomerase immortalized
PNFF ﬁbroblasts were super-infected with pBABE-HYGRO-derived
retroviruses and selected using 400 ng/mL of hygromycin
(Invitrogen). Expression of ectopic hMpn1 variants was veriﬁed
by western blot analysis of total protein extracts using anti HA rab-
bit monoclonal antibodies (C29F4, Cell Signaling) and anti UPF1
goat polyclonal antibodies (A300-036A, Bethyl Laboratories; load-
ing control).
Fig. 4. U6atac stability in PN cells. (A) PNFF-ev and PNFF-hMPN1 cells were
incubated with Actinomycin D (ACTD) and total RNA was prepared at the indicated
time points after ACTD addition. U6, U6atac, VTRNA1-1 and U5 (loading control)
were detected by northern blotting. (B) Quantiﬁcations of the indicated RNAs after
normalization through U5 signals. Values are expressed as fold change over time 0.
Data points and error bars are averages and S.D. from 3 independent experiments.
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Total yeast RNA was extracted with hot phenol according to
published protocols [22]. Total human RNA was prepared with
TRIzol (Invitrogen) followed by puriﬁcation with the Direct-zol
kit (Zymo Research). RNA was subjected to DNAse I (Qiagen) diges-
tion before further procedures. For RNA ligations, 120 pmol of 50
phosphorylated adaptor oligonucleotide were mixed with 3 lg of
RNA, heated to 65 C for 5 min and incubated on ice for 2 min.
For Thaliana tRNA ligase (a kind gift of J. Hesselberth), ligations
were carried out for 2 h at 37 C in 25 mM Tris–HCl pH 7.5,
50 mM NaCl, 5 mMMgCl2, 1 mM DTT, 1 mM ATP (NEB) in presence
of 6 pmol of Thaliana tRNA ligase and 40 U of RNaseOUT(Invitrogen). For T4 RNA ligase, ligations were performed for 16 h
at 16 C in 12% PEG 8000, 1 T4 RNA ligase buffer, 1 mM ATP
(NEB) in presence of 20 U of T4 RNA ligase (NEB) and 40 U of
RNaseOUT. RNA was mixed with 2 loading buffer (8 M Urea,
20 mM EDTA, 5 mM Tris–HCl pH 7.5), heated at 90 C for 5 min
and separated in 17% Tris–Borate–EDTA polyacrylamide gels
(19:1) containing 8 M urea. RNA was then transferred to nylon
membranes (GE Osmonics) and hybridized to DNA oligonu-
cleotides radioactively labeled using T4 polynucleotide kinase
(NEB). Radioactive signals were detected using a Typhoon FLA
9000 Biomolecular Imager (GE Healthcare) and analyzed using
ImageJ (National Institutes of Health, MD, USA) and Adobe
Photoshop. Oligonucleotides are listed in Supplemental Table S2.
4.4. Next generation sequencing of >p-containing transcriptomes
10 lg of total yeast or human RNA was ligated to Thaliana_lig_2
adaptor oligonucleotides (Supplemental Table S2) using Thaliana
tRNA ligase as described above. RNA was puriﬁed and treated with
20 U of rSAP in rSAP buffer (Affymetrix) at 37 C for 1 h in order to
remove 20 phosphate groups. RNA was fragmented with the RNA
fragmentation reagent (Ambion) and then reverse transcribed
using oligonucleotides complementary to the ligated RACE adaptor
(Supplemental Table S2). cDNA was sequenced on an Illumina next
generation sequencing platform at Fasteris (Plan-les-Ouates,
Switzerland). For sequence analysis, adapter sequences were
removed from the obtained reads and trimmed reads were mapped
against the human genome (assembly hg19) or the S. pombe gen-
ome (assembly ASM294v1.17) using the RUM aligner (version
2.0.4) with default settings. A reference collection consisting of
genes and features from the RepeatMasker database (http://
www.repeatmasker.org) was then created and each aligned read
was if possible assigned to one of these features using
HTSeq-count. To construct the count vector, reads mapping to mul-
tiple (N) genomic locations were deﬁned to contribute ‘1/N count’
to each of the assigned features. The obtained read count vectors
were normalized between each pair of Mpn1-proﬁcient and
-deﬁcient samples using the TMMmethod [23]. Features for which
the normalized count in the Mpn1-proﬁcient sample exceeded
800, and for which there was at least a 10-fold increase in the nor-
malized count in the Mpn1-proﬁcient sample compared to the
Mpn1-deﬁcient one were considered potential Mpn1 substrates
(Supplemental Table S1). For yeast and human U6 as well as for
U6atac and VTRNA1-1, we constructed plots showing the read cov-
erage along each feature in the Mpn1-proﬁcient and -deﬁcient
samples, after adjusting for differences in library size. Sequencing
data have been submitted to the Gene Expression Omnibus
(GEO) database (accession number GSE60198).
4.5. 30 Race
Total RNA was treated with T4 polynucleotide kinase (NEB) at
pH 6.0, in order to remove any 30 phosphate group, and succes-
sively puriﬁed with the RNA clean and concentrator kit (Zymo
Research). 120 pmol of 50 phosphorylated 30RACE_AD1 oligonu-
cleotide (Supplemental Table S2) were mixed with 3 lg of puriﬁed
RNA and ligated with T4 RNA ligase as above. 1 lg of ligated RNA
was reverse-transcribed with Superscript III (Invitrogen) using
adapter-speciﬁc oligonucleotides (Supplemental Table S2). cDNA
was PCR-ampliﬁed with 30inner + ill_A and gene speciﬁc oligonu-
cleotides (Supplemental Table S2) using the Phusion
High-Fidelity PCR kit (Thermo Scientiﬁc). PCR products were
sequenced on an Illumina next generation sequencing platform
at Fasteris (Plan-les-Ouates, Switzerland). Each fragment was
sequenced from both ends, generating paired-end reads of 100 nt
each. Adapter sequences were removed using Cutadapt [24] and
V. Shchepachev et al. / FEBS Letters 589 (2015) 2417–2423 2423trimmed reads were aligned to the U6 reference sequence using
BLAT [25]. For ﬁssion yeast samples, information from both reads
in a pair was used to determine whether the read stemmed from
a full-length, intronless RNA species, and to extract the 30 end ter-
minal nucleotides. The same procedure, with a suitable reference
sequence, was used for the 30 RACE analyses of full-length human
U6, U6atac and VTRNA1-1. Sequencing data have been submitted
to the Gene Expression Omnibus (GEO) database (accession num-
ber GSE60198).
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